Yun Fan

21PUBLICATIONS
88CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jan 13, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Anna Li, Wei-Neng Feng, Juan Li

|Dec 31, 2025
Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.

Yi-Long Wu, Li Zhang, Yun Fan

|Dec 13, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial.

Wenfeng Fang, Jian Fang, Panwen Tian

|Nov 06, 2025
Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.

Sizhe Yu, Hui Li, Hongyang Lu

|Sep 15, 2025
Comparative investigation of neoadjuvant chemoimmunotherapy versus perioperative (chemo)immunotherapy in resectable non-small cell lung cancer: a real-world retrospective cohort study.

Yehao Yang, Sini Li, Qian Zhang

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

Pageof 4

Frequent Collaborators

5 joint publications

Kaiyan Chen

4 joint publications

Hui Li

4 joint publications

Mingying Xie

4 joint publications

Zichao Zhou